LOXO-195 Chemical Properties

Density 

1.51±0.1 g/cm3(Predicted)

pka

11.44±0.40(Predicted)

InChI

InChI=1S/C20H21FN6O/c1-12-4-5-16-14(9-13(21)10-22-16)17-3-2-7-26(17)18-6-8-27-19(25-18)15(11-23-27)20(28)24-12/h6,8-12,17H,2-5,7H2,1H3,(H,24,28)/t12?,17-/m1/s1

InChIKey

OEBIHOVSAMBXIB-RGUGMKFQSA-N

SMILES

N12CCC[C@]1([H])C1=CC(F)=CN=C1CCC(C)NC(=O)C1C=NN3C=CC2=NC=13

LOXO-195 Usage And Synthesis

Description

LOXO-195 is an orally available, highly potent, and selective TRK kinase inhibitor designed to overcome drug resistance mediated by acquired mutations. Although responses to TRK inhibition can be dramatic and durable; however, eventually emergence of acquired resistance is found to be inevitable.

Uses

(3aR)-Selitrectinib ((3aR)-LOXO-195) is an isform of Selitrectinib (HY-101977), which is a next-generation TRK kinase inhibitor, with IC50s of 0.6 nM and <2.5 nM for TRKA and TRKC, respectively[1].

References

[1] Drilon A, et al. A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors. Cancer Discov. 2017 Sep;7(9):963-972. DOI:10.1158/2159-8290.CD-17-0507

LOXO-195(1350884-56-8)Related Product Information

• Repotrectinib
• Entrectinib
• LOXO-195
• NVP-BKM120 (Hydrochloride)
• Crizotinib
• Lorlatinib (PF-06463922)